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Evaluation of treatment-related mortality
among paediatric cancer deaths: a population
based analysis
Jason D Pole1, Paul Gibson2, Marie-Chantal Ethier3, Tanya Lazor3, Donna L Johnston4, Carol Portwine5,
Mariana Silva6, Sarah Alexander7 and Lillian Sung*,3,7 on behalf of the International Pediatric Oncology
Mortality Classification (IPOMC) Group
1Pediatric Oncology Group of Ontario, 480 University Ave., Toronto, Ontario, M5G 1V2, Canada; 2Division of Haematology/
Oncology, Children’s Hospital, London Health Sciences Centre, 800 Commissioners Rd. E., London, Ontario, N6A 5W9, Canada;
3Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 686 Bay
St., Toronto, Ontario, M5G 0A4, Canada; 4Department of Pediatrics, Division of Hematology/Oncology, Children’s Hospital of
Eastern Ontario, 401 Smyth Rd, Ottawa, Ontario, K1H 8L1, Canada; 5Department of Pediatrics, McMaster Children’s Hospital, 1280
Main St West, Hamilton, Ontario, L8N 3Z5, Canada; 6Department of Pediatrics, Kingston General Hospital, 76 Stuart St, Kingston,
Ontario, K7L 2V7, Canada and 7Department of Pediatrics, Division of Haematology/Oncology, The Hospital for Sick Children, 555
University Ave., Toronto, Ontario, M5G 1X8, Canada
Background: Objectives were to describe the proportion of deaths due to treatment-related mortality (TRM) and to identify risk
factors and probable causes of TRM among paediatric cancer deaths in a population-based cohort.
Methods: We included children with cancer p18 years diagnosed and treated in Ontario who died between January 2003 and
December 2012. Deaths were identified using a provincial registry, the Pediatric Oncology Group of Ontario Networked
Information System. Probable causes of TRM were described.
Results: Among the 964 deaths identified, 821 were included. The median age at diagnosis was 6.6 years (range 0–18.8) and 51.8%
had at least one relapse. Of the deaths examined, TRM occurred in 217/821 (26.4%) while 604/821 (73.6%) were due to progressive
cancer. Deaths from TRM did not change over time. Using multiple regression, younger age, leukaemia diagnosis and absence of
relapse were independently positively associated with TRM. The most common probable causes of TRM were respiratory,
infection and haemorrhage.
Conclusions: TRM was responsible for 26.4% of deaths in paediatric cancer. Underlying diagnosis, younger age and absence of
relapse were associated with TRM and causes of TRM differed by diagnosis group. Future work should evaluate TRM rate and risk
factors among newly diagnosed cancer patients.
Most children diagnosed with cancer in Canada, the United States
and Europe will be cured (Craft, 2000). As the success of cancer-
directed strategies continues to improve, treatment-related mortality
(TRM), a devastating outcome of a cancer diagnosis, is becoming
increasingly important (Ethier et al, 2011; Blanco et al, 2012). In order
to reduce TRM, it is first important to understand its frequency and
associated risk factors. Understanding TRM versus cancer-related
death is fundamental to identifying the best strategies to improve
survival. If progressive cancer is the primary cause of death, then
strategies will need to focus on treatment intensification or innovative
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approaches to cancer control. However, if TRM is the primary cause
of death, then strategies will need to focus on enhancing supportive
care or may even consider a reduction in treatment intensity.
We previously identified the lack of consistency in TRM
definitions, which made epidemiological studies and comparisons
between trials difficult or impossible to interpret (Ethier et al, 2011;
Tran et al, 2014). For patients with TRM, we also noted the lack of
a consistent cause-of-death attribution system, for example, criteria
to define infection or haemorrhage as the cause of death.
Consequently, we recently developed a standardised TRM defini-
tion and cause-of-death attribution system (Alexander et al, 2015).
With this system, TRM is defined by death occurring in the
absence of progressive cancer. This approach is important as many
children with refractory disease will die from toxicities of therapy.
The system allows flexibility as individual trials may choose to
censor patients who relapse or those who undergo haematopoietic
stem cell transplantation (HSCT). The developed TRM system was
reliable and demonstrated criterion validity (Alexander et al, 2015).
Little is known about the epidemiology of TRM using this novel
definition and cause-of-death attribution system. Taking a
population-based approach to such an epidemiological study is
advantageous as children enrolled on clinical trials are a biased
subgroup of all paediatric cancer cases and in particular, will
typically exclude patients who die before treatment initiation or
those deemed ‘too sick’ for enrollment. Thus, our objective was to
describe the proportion of deaths due to TRM and to identify risk
factors and causes of TRM in a population-based cohort.
MATERIALS AND METHODS
This study was approved by the Research Ethics Board at The
Hospital for Sick Children (SickKids), Toronto, Canada and all
participating centers. The requirement for informed consent was
waived at all sites given the retrospective nature of the study.
The classification system defines TRM as deaths occurring in
the absence of progressive cancer (Alexander et al, 2015). For TRM
cases, causes of death are classified by evaluating the medical
records 2 weeks prior to the death and categories for cause of death
are: infection, haemorrhage, thrombosis, cardiac system, immune
mediated, metabolic, nervous system, respiratory system, gastro-
intestinal (GI) system, renal system and external causes. These
etiologies are classified as probably, possibly or not the cause of
death as previously described (Alexander et al, 2015). The
approach allows multiple probable causes of death to be described.
It also allows TRM to be designated before starting cancer therapy
as treatment initiation in a critically ill child will vary depending on
physician and family preferences, and because some of the deaths
may be preventable with enhanced supportive care.
Setting and patients. The population consisted of children
diagnosed and treated in the province of Ontario, Canada. There
are five centers in Ontario that provide care for paediatric cancer
patients, namely London Health Sciences Centre (London),
Hamilton Health Sciences Centre (Hamilton), SickKids (Toronto),
Cancer Centre of Southeastern Ontario at Kingston (Kingston) and
Children’s Hospital of Eastern Ontario (Ottawa). All centers
report the data to the Pediatric Oncology Group of Ontario
Networked Information System (POGONIS). POGONIS has been
collecting information prospectively on all cases of paediatric
cancer diagnosed and treated in the province of Ontario since
1985.
We included all deaths reported to POGONIS between
1 January 2003 and 31 December 2012 and eligible children were
p18 years at cancer diagnosis. We excluded patients that had an
unconfirmed cancer diagnosis. Children who had not been seen
Deaths identified in POGONIS
during study period
(n = 964) 
Did not meet eligibility criteria
(n = 7)
• Still alive (n = 2)
• >18.99 years at diagnosis (n = 1)
• Died outside the study period (n = 1)
• Uncertain or unconfirmed cancer 
  diagnosis (n = 3)
Excluded from analysis (n = 136)
• Not seen within 1 year or no 
  longer cared for by POGO center
  and died in a non-POGO center 
Included in final analysis
(n = 821)
Treatment-related mortality
(n = 217)
Progressive disease
(n = 604)
Figure 1. Flow diagram of case identification and selection.
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within 1 year prior to death or who were no longer cared for by
clinicians from a Pediatric Oncology Group of Ontario (POGO)
center and who died in a non-POGO center were considered
inevaluable and excluded from the analysis unless sufficient
documentation existed to support a TRM designation.
Design. Trained clinical research associates (CRAs) traveled to
each of the five Ontario institutions in order to abstract the
required information for TRM designation and cause-of-death
attribution. In the designation of TRM, we did not censor at
relapse or HSCT as our intent was to describe TRM in all children
with cancer. Demographic information was abstracted from the
medical records and from the data submitted to POGONIS. The
data included details related to diagnosis, relapse, subsequent
malignancy and receipt of allogeneic or autologous HSCT. The
data regarding receipt of chemotherapy, radiotherapy and cancer-
removing surgery were collected within 2 months prior to death.
A group of 6 CRAs received training on the TRM and cause-of-
death attribution system and their skills were evaluated with 10
randomly chosen cases. Skill level was considered adequate if
assignment of TRM was correct in at least 9 of 10 cases; the correct
response was determined by two paediatric oncologists (SA and
LS). Once competency was deemed adequate, CRAs designated all
cases as TRM or not TRM and if TRM, determined the probable
and possible causes of death.
Statistics. We described the characteristics of the population and
TRM cases using descriptive statistics. Factors associated with
TRM were evaluated using univariate and multiple logistic
regression, and associations were described using odds ratios
(ORs) with 95% confidence intervals (CIs). Variables considered in
the multiple regression model were baseline characteristics and not
treatment factors (since these may be in the causal pathway) or
factors occurring at the time of death such as withdrawal of
supportive care or performing an autopsy (since these would not
have been related to the etiology of death). Statistical significance
was defined as P-valueo0.05. Statistical analysis was conducted
using the SAS statistical program (SAS-PC, version 9.4; SAS
Institute Inc, Cary, NC, USA).
Role of the funding source. The study funding source (POGO)
had no role in study design, data collection, analysis, interpretation,
writing of the report, or decision to submit the paper for
publication.
RESULTS
Among the training cases, TRM designations were correct in 10
out of 10 cases for all 6 CRAs, meeting criteria for adequate skill
level. Cause-of-death attributions were completely correct in 10 out
of 10 cases for 3 CRAs, 9 out of10 cases for 2 CRAs and 8 out of 10
for 1 CRA.
There were 964 deaths identified in POGONIS during the study
period. Figure 1 illustrates the flow diagram of subject identifica-
tion and selection and reasons for exclusion. Characteristics of the
821 included cases are shown as Table 1, both for the entire cohort
and stratified by underlying diagnosis. The median age at diagnosis
Table 1. Demographics of the study population stratified by underlying diagnosis
Total Leukaemia/Lymphoma Solid tumours Brain tumours
N¼821 N¼271 N¼325 N¼225
Characteristics
Male gender 469 (57.1%) 164 (60.5%) 186 (57.2%) 119 (52.9%)
Median age (range) in years at diagnosis 6.6 (0.0 to 18.8) 8.2 (0.0 to 18.8) 5.4 (0.0 to 18.8) 6.4 (0.0 to 18.0)
At least one Relapse 425 (51.8%) 171 (63.1%) 171 (52.6%) 84 (37.3%)
Treatment Within Two Months of Death
Chemotherapy or HSCT conditioning 528 (64.3%) 175 (64.6%) 203 (62.5%) 150 (66.7%)
Surgery or Radiotherapy 152 (18.5%) 12 (4.4%) 113 (34.8%) 27 (12.0%)
HSCT any time 252 (30.7%) 135 (49.8%) 94 (28.9%) 22 (9.8%)
Allogeneic 131 (52.0%) 119 (88.1%) 11 (11.7%) 1 (4.5%)
Autologous 120 (47.6%) 16 (11.9%) 83 (88.3%) 21 (95.5%)
Median days (IQR) last chemotherapy to death 38.0 (11.0, 110.0) 30.0 (7.0, 96.0) 42.0 (14.5, 115.0) 46.0 (14.0, 153.0)
Death prior to 1 January 2007 344 (41.9%) 124 (45.8%) 122 (37.5%) 98 (43.6%)
Death information
Median months to death from diagnosis (IQR) 16.3 (7.5, 36.2) 16.9 (7.5, 42.3) 17.8 (7.9, 35.2) 14.0 (6.8, 30.8)
Withdrawal of supportive care 131 (16.0%) 69 (25.5%) 38 (11.7%) 24 (10.7%)
Location of death
Emergency department 11 (1.3%) 6 (2.2%) 2 (0.6%) 3 (1.3%)
Intensive care unit 200 (24.4%) 114 (42.1%) 56 (17.2%) 30 (13.3%)
Ward 259 (31.5%) 80 (29.5%) 105 (32.3%) 74 (32.9%)
Home 294 (35.8%) 57 (21.0%) 135 (41.5%) 101 (44.9%)
Hospice 29 (3.5%) 4 (1.5%) 17 (5.2%) 8 (3.6%)
Unknown 26 (3.2%) 9 (3.3%) 9 (2.8%) 8 (3.6%)
Othera 3 (0.4%) 1 (0.4%) 1 (0.3%) 1 (0.4%)
Status at death
No evidence of disease 99 (12.1%) 80 (29.5%) 13 (4.0%) 6 (2.7%)
Non-progressive disease 118 (14.4%) 55 (20.3%) 40 (12.3%) 23 (10.2%)
Progressive disease 605 (73.7%) 136 (50.2%) 273 (84.0%) 196 (87.1%)
Autopsy performed 141 (17.2%) 52 (19.2%) 46 (14.2%) 43 (19.1%)
Treatment-related mortality 217 (26.4%) 135 (49.8%) 53 (16.3%) 29 (12.9%)
Abbreviations: HSCT¼ haematopoietic stem cell transplant; IQR¼ interquartile range.
aOther: operating room (n¼ 2); car accident (n¼ 1).
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was 6.6 years (range 0–18.8) and 51.8% of subjects had at least one
relapse. Overall, 30.7% had undergone HSCT with a similar
number receiving allogeneic and autologous transplants although
leukaemia and lymphoma patients predominantly had allogeneic
HSCTs while patients with solid and brain tumours predominantly
had autologous HSCTs. The median number of months from
diagnosis to death was 16.3 (interquartile range 7.5–36.2). For all
children combined, TRM occurred in 217/821 (26.4%) of deaths.
Seventeen of the TRM cases died before cancer treatment was
received.
Table 2 identifies factors associated with TRM. There was no
association between TRM and more recent death (on or after 1
January 2007). The following were significantly positively asso-
ciated with TRM in univariate analysis: leukaemia/lymphoma vs
solid tumour, absence of relapse, chemotherapy or absence of
surgery/radiotherapy within 2 months of death, receipt of HSCT,
shorter time from diagnosis to death, withdrawal of supportive
care, location of death and performing an autopsy. In multiple
regression which considered underlying diagnosis, age and relapse,
all three factors were independently associated with TRM.
Increasing age at diagnosis (OR: 0.92, 95% CI: 0.89–0.95), brain
tumour (OR: 0.54, 95% CI: 0.32–0.91) and relapse (OR: 0.11, 95%
CI: 0.07–0.17) were associated with a lower risk of TRM, while
leukaemia/lymphoma (OR: 11.18, 95% CI: 6.94–18.60) was
associated with a higher risk of TRM.
Most TRM cases had multiple probable or possible causes of
death with only 34 (15.7%) having a single probable or possible
cause of death. Probable causes of death are shown in Table 3. The
most common probable causes of death were respiratory system
failure followed by infection, haemorrhage, GI system failure and
nervous system failure. Most of the 140 deaths with respiratory
system failure as a probable cause of death were concurrent with
infection as another cause of death. More specifically, 87 (62.1%)
cases of respiratory system failure as a probable cause of death were
concurrent with infection as a probable cause of death and 31
(22.1%) were concurrent with infection as a possible cause of
death. Among the 17 who died before cancer treatment initiation,
the most common probable causes of death were nervous system
failure (n¼ 10), respiratory system failure (n¼ 7), haemorrhage
(n¼ 8) and infection (n¼ 4).
Among TRM cases, the proportion of patients with probable
causes of death for the following etiologies differed based on
underlying diagnosis: respiratory system failure, infection, GI
system failure, nervous system failure and renal system failure.
More specifically, respiratory system failure as a probable cause of
death was most common among solid tumour patients, while
infection as a probable cause of death was most common among
leukaemia/lymphoma patients and least common among brain
tumour patients. GI system failure as a probable cause of death was
most common among solid tumour patients while nervous system
failure as a probable cause of death was most common among
brain tumour patients. Thrombosis, metabolic and external causes
were rare causes of death.
Table 4 and Supplementary Material explore infectious probable
causes of TRM. Bacteria were more common than fungi and the
most common infections associated with TRM were coagulase
negative Staphylococcus (n¼ 19), Aspergillus species (n¼ 10) and
Candida spp (n¼ 17). Fungal infections were most common
Table 2. Univariate logistic regression evaluating factors associated with Treatment-related mortality
TRM
N¼217
Progressive disease
(N¼604) OR (95% CI) P-valuea
Characteristics
Male Gender 117 (53.9%) 352 (58.3%) 0.84 (0.62 to 1.15) 0.277
Median Age (Range) in Years at Diagnosis 5.5 (1.4 to 13.0) 7.1 (0.0 to 18.8) 0.96 (0.94 to 0.99) 0.013
Underlying Diagnosis o0.0001
Leukaemia or lymphoma 135 (62.2%) 136 (22.5%) 5.11 (3.52 to 7.51)
Solid tumour 53 (24.4%) 272 (45.0%) REF
Brain tumour 29 (13.4%) 196 (32.5%) 0.76 (0.46 to 1.23)
Relapse 66 (30.4%) 359 (59.4%) 0.30 (0.21 to 0.41) o0.0001
Treatment within two months of death
Chemotherapy 163 (75.1%) 365 (60.4%) 1.98 (1.40 to 2.82) 0.0001
Surgery or radiotherapyb 20 (9.2%) 132 (21.9%) 0.36 (0.21 to 0.58) o0.0001
HSCT any time 81 (37.3%) 170 (28.1%) 1.54 (1.11 to 2.14) 0.009
Allogeneic 68 (84.0%) 63 (37.1%)
Autologous 13 (16.0%) 107 (62.9%)
Median days (IQR) last chemotherapy to death 26.5 (7.0 to 82.0) 47.0 (14.0 to 125.0) 1.0 (1.0 to 1.0) 0.899
Death Prior to 1 January 2007 98 (45.2%) 246 (40.7%) 1.20 (0.88 to 1.64) 0.257
Death information
Median months to death from diagnosis (IQR) 7.8 (0.9 to 25.4) 18.3 (10.2 to 38.1) 0.99 (0.99 to 1.0) 0.019
Withdrawal of supportive care 100 (46.1%) 31 (5.1%) 15.77 (10.18 to 25.05) o0.0001
Location of death o0.0001
Emergency department 5 (2.3%) 6 (1.0%)
Intensive care unit 162 (74.7%) 38 (6.3%)
Ward 36 (16.6%) 223 (36.9%)
Home 8 (3.7%) 285 (47.2%)
Hospice 2 (0.9%) 27 (4.5%)
Unknown 1 (0.5%) 25 (4.1%)
Other 3 (1.4%) 0 (0.0%)
Autopsy Performed 87 (40.1%) 54 (8.9%) 6.82 (4.63 to 10.11) o0.0001
Abbreviations: HSCT—haematopoietic stem cell transplantation; IQR¼ interquartile range; OR¼odds ratio; CI—confidence interval; REF¼ reference category for logistic regression;
TRM¼ treatment-related mortality.
aP-value by logistic regression.
bExcludes radiation used as conditioning for HSCT.
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among those with leukaemia or lymphoma. The most common
sites of infection for TRM cases were blood (n¼ 112) and tissue
biopsy (n¼ 23).
DISCUSSION
Using the newly developed international consensus definitions of
TRM, approximately one in four paediatric cancer deaths were
classified as TRM. Independent risk factors for TRM were younger
age, underlying diagnosis and absence of relapse. The most
common probable causes of TRM were respiratory system failure,
infection and haemorrhage, and probable causes of TRM differed
by underlying diagnosis. This study is important as paediatric
patients receiving intensive treatments still experience unaccep-
tably high TRM (Balduzzi et al, 2002; Creutzig et al, 2004). Our
results are foundational as they provide a basis for future
epidemiological studies of TRM and design of supportive care
strategies to reduce toxic mortality.
We found that the proportion of deaths due to TRM did not
change over time. In contrast, others have noted reduced TRM
over time when intensive therapies are introduced, such as for
acute myeloid leukaemia treatment and HSCT (Jastaniah et al,
Table 4. Microbiological Causes of Treatment-Related Mortality
Total Leukaemia/lymphoma Solid tumours Brain tumours
Organism Namea N¼109 N¼76 N¼27 N¼6
Gram positive 45 32 8 5
Coagulase negative Staphylococcus 17 13 3 1
Clostridium difficile 6 3 1 2
Enterococcus spp 5 3 1 1
Staphylococcus aureus 5 4 1 0
Viridans group streptococci 4 3 1 0
Streptococcus NOS 3 1 1 1
Bacillus NOS 2 2 0 0
Clostridium perfringens 1 1 0 0
Clostridium septicum 1 1 0 0
Micrococcus NOS 1 1 0 0
Gram negative 28 17 10 1
Pseudomonas aeruginosa 8 6 2 0
Enterobacter cloacae 5 2 2 1
Escherichia coli 4 2 2 0
Citrobacter freundii 3 0 3 0
Klebsiella pneumonia 3 3 0 0
Serratia marcescens 2 1 1 0
Stenotrophomonas maltophilia 2 2 0 0
Haemophilus influenza 1 1 0 0
Fungal 36 27 9 0
Aspergillus spp 10 8 2 0
Candida non-albicans 9 8 1 0
Candida albicans 7 3 4 0
Fungi NOS 4 3 1 0
Alternaria NOS 1 1 0 0
Candida NOS 1 1 0 0
Fusarium solani 1 1 0 0
Mucormycosis 1 1 0 0
Mold NOS 1 0 1 0
Pneumosystis jirovecii 1 1 0 0
Abbreviation: NOS¼ not otherwise specified.
aSome patients had multiple infections.
Table 3. Probable Causes of Treatment-Related Mortality Stratified by Underlying Diagnosis
Total Leukaemia/Lymphoma Solid tumours Brain tumours
N¼217 N¼135 N¼53 N¼29 P-valuea
Probable cause of death
Respiratory System 140 (64.5%) 87 (64.4%) 43 (81.1%) 10 (34.5%) 0.0001
Infection 109 (50.2%) 78 (57.8%) 26 (49.1%) 5 (17.2%) 0.0004
Haemorrhage 80 (36.9%) 47 (34.8%) 21 (39.6%) 12 (41.4%) 0.715
GI System 64 (29.5%) 38 (28.1%) 23 (43.4%) 3 (10.3%) 0.006
Nervous System 63 (29.0%) 35 (25.9%) 12 (22.6%) 16 (55.2%) 0.004
Renal System 59 (27.2%) 42 (31.1%) 16 (30.2%) 1 (3.4%) 0.009
Cardiac 38 (17.5%) 23 (17.0%) 13 (24.5%) 2 (6.9%) 0.129
Immune Mediated 28 (12.9%) 19 (14.1%) 9 (17.0%) 0 (0.0%) 0.073
Thrombosis 7 (3.2%) 7 (5.2%) 0 (0.0%) 0 (0.0%) 0.111
Metabolic 4 (1.8%) 3 (2.2%) 1 (1.9%) 0 (0.0%) 0.722
External Causes 1 (0.5%) 1 (0.7%) 0 (0.0%) 0 (0.0%) 0.737
Abbreviation: GI¼gastrointestinal.
aP-values by w2 test.
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2012; Altshuler et al, 2016). One explanation for this discrepancy is
the different metric used, as we evaluated the proportion of deaths
as opposed to the proportion of patients with TRM. An important
next step would be to evaluate a cohort of newly diagnosed
paediatric cancer patients and to describe the TRM rate and risk
factors for TRM among these patients.
We also found that leukaemia diagnosis, younger age and
absence of relapse were risk factors for TRM. Most studies of TRM
have focused on specific patient populations and thus, our
approach is unique. The finding of increased TRM in patients
with leukaemia/lymphoma and patients without relapse is
expected. However, the finding of increased TRM in younger
patients is surprising, given that in the context of acute myeloid
leukaemia, older age (Canner et al, 2013) and obesity (Lange et al,
2005) have been associated with increased TRM. These conflicting
data may relate to the limited upper age range in our study (18
years) or the difference in metric as previously described. We also
found that invasive fungal disease, and in particular, both molds
and yeasts are common probable causes of TRM. This finding
suggests that approaches to prevent and treat fungal disease should
be a priority for future research.
We previously asked whether CRAs can abstract this type of
data or whether physicians should ultimately be classifying TRM
and cause-of-death attributions. We found that with minimal
training, all CRAs were able to correctly distinguish TRM vs
progressive cancer and that attribution classification was excellent.
We will continue to develop educational materials to enhance
reliable TRM and cause-of-death attribution for future studies.
The strength of this study is the use of consistent and trained
CRAs to abstract all the data for this analysis. A second strength is
the population-based nature of the study, which improves
generalizability and avoids selection bias. However, our results
must be interpreted in light of its limitations. The most important
limitation is that, we did not describe the TRM rate among all
newly diagnosed cancer patients. We took the approach of first
evaluating TRM among all deaths as a pragmatic initial step since
we needed to evaluate all deaths to determine which ones were
TRM and evaluation of TRM among all cancer patients will require
the additional data about those who did not die. Nonetheless,
evaluating the TRM rate among newly diagnosed cancer patients is
planned as a future next step. Also, we often did not have adequate
documentation to classify TRM for patients who transitioned to
adult care, a subgroup of patients of particular importance given
known disparities for adolescent and young adult patients
(Nachman, 2003).
In conclusion, TRM was responsible for 26.4% of deaths in
paediatric cancer. Underlying diagnosis, younger age and absence
of relapse were associated with TRM and causes of TRM differed
by diagnosis group. Future work should evaluate TRM rate and
risk factors among newly diagnosed cancer patients.
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